MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, ZVSA had -$1,429,146 decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$1,429,146
Unit: Dollar
Positive Cash Flow Breakdown
    • Impairment of in-process researc...
    • Warrant inducement offer - exerc...
    • Private placement of warrants
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Deferred tax (benefit) provision
    • Registration and issuance costs ...
    • Prepaid expenses and other curre...

Cash Flow
2025-12-31
Non-cash rent expense
0
Operating lease liability
0
Depreciation of fixed assets
0
Net loss
-24,952,378
Impairment of in-process research and development
18,647,903
Stock-based compensation
222,831
Issuance of common stock pursuant to vendor agreements
240,000
Write-off of deferred offering costs
57,238
Deferred tax (benefit) provision
-851,659
Prepaid expenses and other current assets
46,766
Accounts payable
689,268
Vendor deposits
161,927
Accrued expenses and other current liabilities
717,255
Net cash used in operating activities
-5,114,381
Exercise of warrants
0
Payment of offering costs
0
At the market issuance of stock proceeds
0
Private placement of warrants
1,999,791
Warrant inducement offer - exercise proceeds
2,051,852
Exercise of pre-funded warrants
210
Registration and issuance costs associated with warrant issuance
366,618
Net cash provided by financing activities
3,685,235
Net decrease in cash
-1,429,146
Cash - beginning of period
1,530,924
Cash - end of period
101,778
Unit: Dollar.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Warrant inducementoffer - exercise...$2,051,852 Private placement ofwarrants$1,999,791 Exercise of pre-fundedwarrants$210 Net cash provided byfinancing activities$3,685,235 Canceled cashflow$366,618 Net decrease in cash-$1,429,146 Canceled cashflow$3,685,235 Impairment of in-processresearch and development$18,647,903 Accrued expenses andother current...$717,255 Accounts payable$689,268 Issuance of common stockpursuant to vendor...$240,000 Stock-based compensation$222,831 Vendor deposits$161,927 Write-off of deferredoffering costs$57,238 Registration and issuancecosts associated with...$366,618 Net cash used inoperating activities-$5,114,381 Canceled cashflow$20,736,422 Net loss-$24,952,378 Deferred tax (benefit)provision-$851,659 Prepaid expenses andother current assets$46,766

ZyVersa Therapeutics, Inc. (ZVSA)

ZyVersa Therapeutics, Inc. (ZVSA)